PHGE
BiomX Inc.
Biotechnology
Market Cap$1.01B
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PHGE vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$176.36B
5Y Perf.+35.9%
PHGE vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PHGE | TMO |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $1.01B | $176.36B |
| Revenue (TTM) | $0.00 | $45.20B |
| Net Income (TTM) | $-36M | $6.86B |
| Gross Margin | — | 39.4% |
| Operating Margin | — | 17.8% |
| Forward P/E | — | 19.1x |
| Total Debt | $1M | $40.85B |
| Cash & Equiv. | $5M | $9.86B |
PHGE vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PHGE
TMO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BiomX Inc. (PHGE) | 100 | 0.1 | -99.9% |
| Thermo Fisher Scien… (TMO) | 100 | 135.9 | +35.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PHGE vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TMO leads in 6 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
PHGE
BiomX Inc.
The Growth Play
PHGE is the clearest fit if your priority is growth exposure.
- EPS growth 20.6%
Best for: growth exposure
TMO
Thermo Fisher Scientific Inc.
The Income Pick
TMO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 8 yrs, beta 1.10, yield 0.4%
- 229.1% 10Y total return vs PHGE's -100.0%
- Lower volatility, beta 1.10, Low D/E 76.3%, current ratio 1.89x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TMO | 3.9% revenue growth vs PHGE's -62.3% |
| Quality / Margins | TMO | 15.2% margin vs PHGE's -0.7% |
| Stability / Safety | TMO | Beta 1.10 vs PHGE's 1.14 |
| Dividends | TMO | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | TMO | +16.8% vs PHGE's -94.3% |
| Efficiency (ROA) | TMO | 6.4% ROA vs PHGE's -80.4%, ROIC 7.5% vs -444.8% |
PHGE vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
PHGE vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTMOLAGGINGPHGE
PHGEBiomX Inc.
2leads
TMOThermo Fisher Scienti…
3leads
6 Total Categories
CATEGORYLEADERvs PHGEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PHGE1/1
Valuation MetricsMultiples, price ratios, and targets
PHGE1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TMO6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
TMO6/6
Risk & VolatilityBeta, volatility, and downside exposure
TMO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PHGE leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TMO and PHGE operate at a comparable scale, with $45.2B and $0 in trailing revenue.
| Metric | PHGEBiomX Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $45.2B |
| EBITDAEarnings before interest/tax | -$28M | $10.5B |
| Net IncomeAfter-tax profit | -$36M | $6.9B |
| Free Cash FlowCash after capex | -$26M | $6.7B |
| Gross MarginGross profit ÷ Revenue | — | +39.4% |
| Operating MarginEBIT ÷ Revenue | — | +17.8% |
| Net MarginNet income ÷ Revenue | — | +15.2% |
| FCF MarginFCF ÷ Revenue | — | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +17.1% | +11.3% |
PHGE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
PHGE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | PHGEBiomX Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $1.0B | $176.4B |
| Enterprise ValueMkt cap + debt − cash | $1.0B | $207.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | 26.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.11x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.67x |
| EV / EBITDAEnterprise value multiple | — | 19.04x |
| Price / SalesMarket cap ÷ Revenue | — | 3.96x |
| Price / BookPrice ÷ Book value/share | — | 3.34x |
| Price / FCFMarket cap ÷ FCF | — | 28.02x |
PHGE leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
TMO leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-3 for PHGE. On the Piotroski fundamental quality scale (0–9), TMO scores 6/9 vs PHGE's 2/9, reflecting solid financial health.
| Metric | PHGEBiomX Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | -2.7% | +13.2% |
| ROA (TTM)Return on assets | -80.4% | +6.4% |
| ROICReturn on invested capital | -4.4% | +7.5% |
| ROCEReturn on capital employed | -66.6% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | — | 0.76x |
| Net DebtTotal debt minus cash | -$4M | $31.0B |
| Cash & Equiv.Liquid assets | $5M | $9.9B |
| Total DebtShort + long-term debt | $1M | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | -33.64x | 5.89x |
TMO leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
TMO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,283 today (with dividends reinvested), compared to $5 for PHGE. Over the past 12 months, TMO leads with a +16.8% total return vs PHGE's -94.3%. The 3-year compound annual growth rate (CAGR) favors TMO at -4.0% vs PHGE's -77.4% — a key indicator of consistent wealth creation.
| Metric | PHGEBiomX Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | -71.1% | -19.8% |
| 1-Year ReturnPast 12 months | -94.3% | +16.8% |
| 3-Year ReturnCumulative with dividends | -98.9% | -11.7% |
| 5-Year ReturnCumulative with dividends | -99.9% | +2.8% |
| 10-Year ReturnCumulative with dividends | -100.0% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -77.4% | -4.0% |
TMO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
TMO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TMO is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than PHGE's 1.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TMO currently trades 73.7% from its 52-week high vs PHGE's 4.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PHGEBiomX Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 1.10x |
| 52-Week HighHighest price in past year | $14.71 | $643.99 |
| 52-Week LowLowest price in past year | $0.61 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +4.2% | +73.7% |
| RSI (14)Momentum oscillator 0–100 | 21.4 | 43.1 |
| Avg Volume (50D)Average daily shares traded | 193K | 1.9M |
TMO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PHGE as "Buy" and TMO as "Buy". Consensus price targets imply 6037.9% upside for PHGE (target: $38) vs 38.0% for TMO (target: $655). TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | PHGEBiomX Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $38.00 | $654.67 |
| # AnalystsCovering analysts | 5 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
Insufficient data to determine a leader in this category.
Key Takeaway
TMO leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). PHGE leads in 2 (Income & Cash Flow, Valuation Metrics).
Best OverallThermo Fisher Scientific In… (TMO)Leads 3 of 6 categories
Loading custom metrics...
PHGE vs TMO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is PHGE or TMO a better buy right now?
Thermo Fisher Scientific Inc.
(TMO) offers the better valuation at 26. 8x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate BiomX Inc. (PHGE) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PHGE or TMO?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 8%, compared to -99. 9% for BiomX Inc. (PHGE). Over 10 years, the gap is even starker: TMO returned +229. 1% versus PHGE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PHGE or TMO?
By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.
(TMO) is the lower-risk stock at 1. 10β versus BiomX Inc. 's 1. 14β — meaning PHGE is approximately 4% more volatile than TMO relative to the S&P 500.
04Which is growing faster — PHGE or TMO?
On earnings-per-share growth, the picture is similar: BiomX Inc.
grew EPS 20. 6% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PHGE or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus 0. 0% for BiomX Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus 0. 0% for PHGE. At the gross margin level — before operating expenses — TMO leads at 37. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is PHGE or TMO more undervalued right now?
Analyst consensus price targets imply the most upside for PHGE: 6037.
9% to $38. 00.
07Which pays a better dividend — PHGE or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. PHGE does not pay a meaningful dividend and should not be held primarily for income.
08Is PHGE or TMO better for a retirement portfolio?
For long-horizon retirement investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +229. 1% 10Y return). Both have compounded well over 10 years (TMO: +229. 1%, PHGE: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between PHGE and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.